Truist analyst Michael Lewis lowered the firm’s price target on American Healthcare REIT to $16 from $17 but keeps a Buy rating on the shares. The company is positioned for sector-leading earnings growth in 2025, supported by continued net operating income growth, easing interest rate pressures and eventual exercise of the Trilogy purchase option, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHR:
- American Healthcare REIT Unveils Supplemental Financial Data
- American Healthcare REIT (“AHR”) Announces Fourth Quarter 2023 and Full Year 2023 Results; Issues Full Year 2024 Guidance
- American Healthcare REIT: Bonuses, Tender Offer, and Quarterly Payout
- American Healthcare REIT initiated with an Overweight at Barclays
- American Healthcare REIT initiated with a Buy at BofA
